ASMT rs73142233: Melatonin Synthesis and Sleep Traits
The genetic variant rs73142233 is a promoter single nucleotide polymorphism located in the ASMT gene, which directs the final enzymatic step in melatonin biosynthesis. Experimental and candidate gene studies have linked this regulatory variant to reduced gene transcription, decreased melatonin production, and altered sleep architecture, including reduced sleep efficiency and chronic insomnia. However, evidence remains limited and is largely drawn from small candidate cohorts rather than large genome-wide association findings.
What each genotype means
Typical Melatonin Synthesis
You carry two copies of the common C allele in the promoter region of the ASMT gene. This genotype is associated with standard baseline ASMT promoter activity, typical melatonin biosynthesis capacity, and an average population baseline for sleep efficiency. Evidence linking this locus to sleep variation is limited and reflects modest statistical shifts in populations rather than a clinical diagnosis of any sleep disorder.
Carried by the vast majority of individuals across diverse ancestries, representing roughly 85% to 92% of individuals in European populations.
Moderately Reduced Melatonin Synthesis
You carry one copy of the less common T allele associated with decreased ASMT promoter transcription. In research cohorts, carrying this allele has been linked to moderately reduced melatonin production and modest statistical increases in vulnerability to insomnia or altered sleep efficiency. Because the clinical evidence remains limited and sleep is influenced by many biological and environmental factors, this genotype does not determine poor sleep quality on its own.
Carried by approximately 8% to 15% of individuals of European ancestry and is generally rare or at very low frequencies in East Asian populations.
Reduced Melatonin Synthesis
You carry two copies of the T allele in the ASMT gene promoter, a combination associated in published studies with lower ASMT enzyme expression and diminished nighttime melatonin output. Studies report a statistical correlation between this reduced-expression profile and lower sleep efficiency or chronic sleep disturbances. However, evidence is currently limited, so this genotype alone is not diagnostic of insomnia or any sleep disorder.
Found in less than 1% of individuals across most global populations, including those of European ancestry.
Genomic Location and the ASMT Gene
The single nucleotide polymorphism rs73142233 sits in the 5-prime regulatory promoter region of the ASMT (acetylserotonin O-methyltransferase) gene. The ASMT locus is uniquely positioned in pseudoautosomal region 1 (PAR1) shared by human sex chromosomes X and Y. Because PAR1 undergoes regular pairing and recombination during male meiosis, genes located here escape typical X-inactivation, meaning both males and females typically possess two active alleles. The primary biochemical function of ASMT is to catalyze the transfer of a methyl group from S-adenosylmethionine to N-acetylserotonin, forming melatonin. This enzymatic step represents the final transformation in the synthesis of melatonin within the pineal gland and the retina. Regulatory variants located in the promoter sequence, such as rs73142233, have the potential to alter binding affinity for nuclear transcription factors, directly modulating the quantity of ASMT messenger RNA transcribed in response to biological circadian cues.
Biological Mechanisms in Melatonin Synthesis
Melatonin serves as the human body's central neurochemical signal for biological darkness, helping synchronize the central master clock located in the suprachiasmatic nucleus with environmental light-dark cycles. Normal melatonin synthesis begins with the amino acid tryptophan, progressing through serotonin and N-acetylserotonin before ASMT performs the terminal methylation. Functional in vitro assays utilizing reporter gene constructs and transformed lymphoblastoid cell lines indicate that the minor allele at rs73142233 correlates with reduced transcriptional activity at the ASMT promoter. When fewer active ASMT enzyme molecules are produced, the conversion rate of N-acetylserotonin into melatonin declines, leading to attenuated nighttime peaks of circulating melatonin. This diminished nocturnal surge can disrupt normal core body temperature lowering and impair the physiological cascade that facilitates rapid sleep onset and consolidated sleep maintenance throughout the night.
Scientific Evidence on Sleep Efficiency and Insomnia
Clinical interest in rs73142233 stems from psychiatric and chronobiology studies evaluating circadian disruption. Candidate association studies have observed that carriers of the minor promoter allele exhibit altered sleep parameters, including reduced sleep efficiency (the ratio of actual time spent asleep to total time spent in bed) and higher reported rates of chronic insomnia. Similar promoter variants in ASMT have also been explored in cohorts with bipolar disorder, major depression, and autism spectrum conditions characterized by comorbid circadian dysfunction. However, scientific evidence supporting rs73142233 remains categorized as limited. Large-scale genome-wide association studies (GWAS) for insomnia and subjective sleep duration have not consistently pinpointed rs73142233 as a genome-wide significant driver. Consequently, while biologically plausible, the variant should be regarded as a subtle modifier of circadian physiology rather than a deterministic cause of sleep disturbance.
Population Distribution and Ancestry Patterns
The alternative allele at rs73142233 is a low-frequency genetic marker globally. In population genomic datasets such as gnomAD and European reference panels, the minor allele frequency typically ranges between 0.04 and 0.08 (4% to 8%). As a result, the vast majority of individuals carry two copies of the common major allele. Heterozygous carriers representing one copy of the variant are relatively uncommon, while homozygous carriers of the alternative allele are rare, occurring in less than 1% of most sampled groups. Allele distribution data across non-European populations, including East Asian, South Asian, and African lineages, remain sparse or show lower frequencies. Further large-scale multi-ancestry sequencing will be required to define precise baseline allele frequencies and assess whether physiological associations persist consistently across diverse demographic backgrounds.
Interpreting Genetic Results in Daily Life
Discovering an alternative allele at rs73142233 provides personal biological context rather than a medical diagnosis. Genetic variants in circadian regulatory pathways operate within a complex web of environmental, behavioral, and polygenic influences. Having a genotype linked to lower ASMT promoter activity does not guarantee you will develop insomnia, nor does carrying the standard reference genotype confer immunity against poor sleep quality. Everyday factors—such as evening exposure to bright or blue light, erratic work schedules, caffeine consumption, stress, and overall sleep hygiene—exert profound effects on endogenous melatonin regulation. Individuals interested in addressing sleep complaints or exploring over-the-counter sleep aids should consult a qualified physician or sleep specialist. Genetic testing results should never be used to initiate or alter prescription medications or hormonal supplements without professional clinical guidance.
How common is this variant?
The minor alternative allele at rs73142233 is relatively uncommon, displaying an estimated frequency of approximately 0.04 to 0.08 (4% to 8%) in populations of European ancestry. Homozygous carriers of the variant allele represent less than 1% of individuals across documented cohorts.
Frequently asked questions
Does having the rs73142233 variant mean I will develop chronic insomnia?
No, carrying this variant does not mean you will inevitably develop insomnia. Sleep architecture is polygenic and deeply affected by environmental cues, daytime habits, stress, and evening light exposure. The variant represents a modest biological predisposition toward reduced melatonin synthesis rather than an absolute medical diagnosis.
Can taking over-the-counter melatonin counteract this genetic variant?
While exogenous melatonin supplements can raise circulating melatonin levels, there are no established clinical guidelines prescribing supplements based solely on this genotype. Optimal timing, dose, and efficacy vary widely between individuals. You should speak with a healthcare provider or pharmacist before starting any sleep supplement to ensure it is appropriate and safe for your circumstances.
What is the biological function of the ASMT gene?
The ASMT gene provides instructions for producing acetylserotonin O-methyltransferase, the enzyme that performs the final step of melatonin creation. It converts N-acetylserotonin into melatonin in the pineal gland and retina, helping govern internal circadian rhythms.
Why is the evidence for rs73142233 considered limited?
Most findings connecting rs73142233 to sleep efficiency and insomnia originate from targeted candidate gene studies and small clinical cohorts. Large genome-wide association studies (GWAS) measuring sleep duration and insomnia have not replicated this variant with genome-wide statistical significance, indicating its individual effect size is modest or context-dependent.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs73142233?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29